CCXI ChemoCentryx Inc

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences:

• 2021 Virtual Wells Fargo Healthcare ConferenceFireside Chat Thursday, September 9 at 4:40 p.m. Eastern Time

• H.C. Wainwright 23rd Annual Global Investment Conference On-demand presentation available beginning Monday, September 13 at 6:00 a.m. Eastern Time

Live audio webcasts of the Wells Fargo fireside chat, as well as the on-demand H.C. Wainwright presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. Replays of both the Wells Fargo and H.C. Wainwright presentations will be available on the Company's website for two weeks following the respective presentation dates.

About ChemoCentryxChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and is in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G).

ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Contacts:

Susan M. Kanaya                                        Executive Vice President,                                         Chief Financial and Administrative Officerinvestor@chemocentryx.com                               

Media: Stephanie Tomei408.234.1279media@chemocentryx.com

Investors:Lee Roth, Burns McClellan212.213.0006 lroth@burnsmc.com